Seres Therapeutics (MCRB) Competitors $0.77 +0.04 (+5.49%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MCRB vs. NKTR, FGEN, HUMA, ABVX, ORGO, ATXS, CRVS, IGMS, SANA, and PRTCShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Nektar Therapeutics (NKTR), FibroGen (FGEN), Humacyte (HUMA), ABIVAX Société Anonyme (ABVX), Organogenesis (ORGO), Astria Therapeutics (ATXS), Corvus Pharmaceuticals (CRVS), IGM Biosciences (IGMS), Sana Biotechnology (SANA), and PureTech Health (PRTC). These companies are all part of the "medical" sector. Seres Therapeutics vs. Nektar Therapeutics FibroGen Humacyte ABIVAX Société Anonyme Organogenesis Astria Therapeutics Corvus Pharmaceuticals IGM Biosciences Sana Biotechnology PureTech Health Seres Therapeutics (NASDAQ:MCRB) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Which has stronger valuation & earnings, MCRB or NKTR? Seres Therapeutics has higher revenue and earnings than Nektar Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.33M1.04-$113.72M-$0.23-3.34Nektar Therapeutics$90.12M2.15-$276.06M-$0.84-1.25 Is MCRB or NKTR more profitable? Seres Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -180.70%. Seres Therapeutics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A N/A -55.08% Nektar Therapeutics -180.70%-173.28%-46.31% Does the media prefer MCRB or NKTR? In the previous week, Seres Therapeutics had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 7 mentions for Seres Therapeutics and 5 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of -0.03 beat Seres Therapeutics' score of -0.37 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, MCRB or NKTR? Seres Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Does the MarketBeat Community favor MCRB or NKTR? Nektar Therapeutics received 100 more outperform votes than Seres Therapeutics when rated by MarketBeat users. However, 72.11% of users gave Seres Therapeutics an outperform vote while only 70.71% of users gave Nektar Therapeutics an outperform vote. CompanyUnderperformOutperformSeres TherapeuticsOutperform Votes53072.11% Underperform Votes20527.89% Nektar TherapeuticsOutperform Votes63070.71% Underperform Votes26129.29% Do analysts recommend MCRB or NKTR? Seres Therapeutics currently has a consensus target price of $5.08, indicating a potential upside of 561.38%. Nektar Therapeutics has a consensus target price of $3.50, indicating a potential upside of 233.33%. Given Seres Therapeutics' higher possible upside, equities analysts plainly believe Seres Therapeutics is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Nektar Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders and institutionals hold more shares of MCRB or NKTR? 59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 5.1% of Seres Therapeutics shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummarySeres Therapeutics beats Nektar Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.23M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-3.3411.10105.1417.83Price / Sales1.04362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book5.4910.377.096.50Net Income-$113.72M$153.60M$119.65M$226.22M7 Day Performance39.82%4.60%2.25%4.03%1 Month Performance1.53%-6.29%-2.33%4.92%1 Year Performance-31.38%33.41%33.98%29.30% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.5834 of 5 stars$0.77+5.5%$5.08+561.4%-31.4%$131.23M$126.33M-3.34233Analyst UpgradeNKTRNektar Therapeutics4.1335 of 5 stars$1.01+1.0%$3.50+246.5%+112.6%$186.31M$90.12M-1.20220FGENFibroGen2.2448 of 5 stars$0.39+11.5%N/A-17.3%$35.27M$180.02M-0.31486Analyst ForecastHUMAHumacyte2.8736 of 5 stars$4.38-0.7%$11.00+151.1%+76.1%$551.27M$1.57M0.00150Insider TradeNews CoverageABVXABIVAX Société Anonyme2.6874 of 5 stars$8.65-2.4%$39.80+360.1%-13.2%$547.46MN/A0.0061ORGOOrganogenesis4.1203 of 5 stars$4.02+1.3%$5.33+32.7%+56.4%$532.97M$433.14M-66.17950ATXSAstria Therapeutics1.8948 of 5 stars$9.41-1.8%$25.60+172.1%+117.3%$531.00MN/A-4.5030CRVSCorvus Pharmaceuticals2.7468 of 5 stars$9.01+9.3%$12.83+42.4%+534.8%$529.48MN/A-9.6930High Trading VolumeIGMSIGM Biosciences4.6736 of 5 stars$8.89-9.0%$16.13+81.4%+64.0%$528.60M$2.13M-2.44190Gap DownSANASana Biotechnology2.2051 of 5 stars$2.35-7.1%$13.50+474.5%-38.6%$524.68MN/A-1.68328PRTCPureTech Health1.8962 of 5 stars$21.78+0.4%$45.00+106.6%+7.1%$521.46M$3.33M0.00100Analyst RevisionNews Coverage Related Companies and Tools Related Companies NKTR Competitors FGEN Competitors HUMA Competitors ABVX Competitors ORGO Competitors ATXS Competitors CRVS Competitors IGMS Competitors SANA Competitors PRTC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MCRB) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
